Coronavirus (COVID-19)
Learn more
March 13, 2013
Location: The Hospital of Central Connecticut
A Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risks MDS and Symptomatic Anemia – temporarily suspended to accrual.
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209